Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis

BACKGROUND AND OBJECTIVES: The University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture gastrointestinal (GI) tract morbidity in patients with systemic sclerosis (SSc). The aims of this study were to deter...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Res Ther
Главные авторы: Zampatti, Norina, Garaiman, Alexandru, Jordan, Suzana, Dobrota, Rucsandra, Becker, Mike Oliver, Maurer, Britta, Distler, Oliver, Mihai, Carina
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8061014/
https://ncbi.nlm.nih.gov/pubmed/33888149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02506-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы